REG - Scancell Hlds - Scancell Appoints Dr Phil L’Huillier as CEO

Scancell HoldingsAnnouncement

22/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241022:nRSV0290Ja&default-theme=true

RNS Number : 0290J  Scancell Holdings Plc  22 October 2024

22 October 2024

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Scancell announces strengthening of leadership team as it closes on
value-generating inflection points

 

Phil L'Huillier PhD, MBA appointed as Chief Executive Officer, bringing 30
years of pharmaceutical industry leadership experience

 

Professor Lindy Durrant remains in Chief Scientific Officer role to continue
to progress Scancell's pioneering immunotherapy work

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer, today announces the appointment of Dr Phil L'Huillier
as Chief Executive Officer (CEO). He will join the company and become a member
of the Company's Board of Directors, effective 18 November 2024. Current Chief
Executive Officer, Professor Lindy Durrant, will remain in the CEO role until
that date. She will also retain her position as Chief Scientific Officer
(CSO), working closely alongside Dr L'Huillier, and will remain on the
Company's Board of Directors.

 

Prior to joining Scancell, Dr L'Huillier served as CEO and Managing Director
of CatalYm GmbH, a pioneering cancer immunotherapy company headquartered in
Munich, Germany. At CatalYm, he was instrumental in expanding the Company's
investor base and profile, successfully leading oversubscribed Series C and D
financing rounds totalling over $200 million. During his tenure, the company
successfully progressed the lead programme from Phase 1 to randomized Phase 2b
clinical studies across several indications. Prior to this, he was Head of the
European Innovation Hub & Business Development for Europe, the Middle East
and Africa at global pharmaceutical company Merck Sharp & Dohme (MSD). As
part of his role, Phil was responsible for the identification and evaluation
of BD opportunities across multiple indications, including oncology. Earlier
in his career, he served as Executive Director and Board Member of Cancer
Research Technology (CRT), a wholly owned for-profit subsidiary of Cancer
Research UK (CRUK). Over the course of his career, Dr L'Huillier has also
simultaneously played key roles in the formation of a number of biotechnology
companies and served as Non-Executive Director for Achilles Therapeutics,
Blink Therapeutics, Revitope Therapeutics, Senectus Therapeutics, PsiOxus
Therapeutics and Hybrid Bioscience.

 

Dr L'Huillier holds a PhD in molecular and cellular biology from the
University of Auckland, New Zealand, as well as an MBA.

 

Dr Jean-Michel Cosséry, Non-Executive Chairman, Scancell said: "Phil is an
accomplished, results-driven leader with a proven track record in developing
and commercialising novel cancer therapeutics. We look forward to drawing on
his deep understanding of the biopharmaceutical industry, as well as his
substantial experience in the immunotherapy space as we progress towards
near-term value-generating inflection points. On behalf of the Board, I warmly
welcome him to Scancell.

 

"I would like to sincerely thank Lindy for her strategic and scientific
guidance during her CEO tenure, which has been instrumental in establishing
the Company as a leader in the immunotherapy space, and I am delighted that
Scancell will continue to benefit from her expertise in her role as CSO."

 

Phil L'Huillier, incoming Chief Executive Officer, Scancell, added: "We are on
the verge of a revolution in cancer therapy, driven by greater understanding
of the human adaptive immune system. I am delighted to join Scancell at such
an exciting juncture, with the company's complementary cancer vaccine
platforms, ImmunoBody® and Moditope®, showing incredible potential in the
clinic. Together with a dynamic and talented management team and Board of
Directors, I am very much looking forward to building on the progress
delivered under Lindy's leadership and realising the full potential of the
core science to improve the lives of patients and create value for investors."

 

Professor Lindy Durrant, Chief Executive Officer and Chief Scientific Officer
added: "When I took on the role of CEO three years ago my priority was to see
our products evaluated in the clinic. We are now successfully delivering the
clinical trials for both SCIB1/iSCIB1+ in melanoma and Modi-1 in various solid
tumours. In addition, our anti-glycan antibody platform continues to yield
exciting results with potential acceleration into the clinic with revenue
generating deals. Scancell is now in a position with exciting clinical data to
move to a late-stage clinical company and this is an excellent opportunity for
Phil to take the company forward and allow me the to refocus my
entrepreneurial skills on developing the portfolio. I would like to thank the
board, employees and Scancell shareholders for their support over the last
three years. I am grateful for the opportunity to have worked alongside such
talented and dedicated individuals and I look forward to supporting Phil and
Scancell as CSO as the company continues to grow and lead the development of
its vaccine and antibody platforms."

 

Additional Information

 

In accordance with the AIM Rules, the following information required to be
disclosed in relation to Phil L'Huillier is set out below. Other than this
information, there is no further information required to be disclosed under
paragraph (g) of Schedule Two of the AIM Rules.

 

Full name and age: Philip John L'Huillier, aged 62

 

 Current directorships/partnerships  Previous directorships/partnerships (last five years)
 98 Brondesbury Park Limited         MPRV Ltd
 CatalYm GmbH
 Samax Holdings Ltd

 

-ENDS-

 

 For further information, please contact:

 Scancell Holdings plc                                                    +44 (0) 20 3709 5700
 Professor Lindy Durrant, CEO

 Dr Jean-Michel Cosséry, Non-Executive Chairman

 Panmure Liberum Limited (Nominated Advisor and Joint Broker)             +44 (0) 20 7886 2500
 Emma Earl/ Freddy Crossley/ Will Goode/ Mark Rogers (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Joint Broker)                                           +44 (0) 20 3705 9330
 David Wilson/ Claes Spang/ Satheesh Nadarajah/ Erland Sternby

 ICR Consilium
 Mary-Jane Elliott/ Angela Gray/ Lindsey Neville                          +44 (0) 20 37095700

                                                                          scancell@consiliumcomms.com (mailto:scancell@consiliumcomms.com)

 
 

About Scancell

 

Scancell is a clinical stage immunotherapy company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer. The Company is building a pipeline of innovative products by utilising
its four technology platforms: Moditope(®) and ImmunoBody(®) for vaccines
and GlyMab(®) and AvidiMab(®) for antibodies. Adaptive immune responses
include antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or infected
cells, Scancell uses either vaccines to induce immune responses or monoclonal
antibodies (mAbs) to redirect immune cells or drugs. The Company's approaches
are that vaccines (ImmunoBody(®) and Moditope(®)) use unique receptors to
target antigens to activated antigen presenting cells whereas its mAb
portfolio targets glycans or sugars that are added onto proteins and / or
lipids (GlyMab(®)) or enhances the potency of antibodies and their ability to
directly kill tumour cells (AvidiMab(®)).

Scancell is headquartered in Oxford, United Kingdom and is listed on AIM
(LSE.SCLP.L). For further information about Scancell, please visit:
https://www.scancell.co.uk. (https://www.scancell.co.uk.)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABIBDGGBDDGSB